Header Logo

Connection

SANJAY MATHEW to Humans

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Humans.
SANJAY MATHEW
Connection Strength
1.249
Humans
  1. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 12 01; 80(12):1187-1188.
    View in: PubMed
    Score: 0.025
  2. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
    View in: PubMed
    Score: 0.024
  3. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology. 2024 Jan; 49(1):189-196.
    View in: PubMed
    Score: 0.024
  4. Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):350-360.
    View in: PubMed
    Score: 0.024
  5. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
    View in: PubMed
    Score: 0.023
  6. Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275.
    View in: PubMed
    Score: 0.023
  7. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. Am J Psychiatry. 2023 03 01; 180(3):190-199.
    View in: PubMed
    Score: 0.023
  8. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.023
  9. An Update on Community Ketamine Practices. Am J Psychiatry. 2022 05; 179(5):393-394.
    View in: PubMed
    Score: 0.022
  10. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opin Drug Saf. 2022 Jun; 21(6):745-759.
    View in: PubMed
    Score: 0.022
  11. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43.
    View in: PubMed
    Score: 0.022
  12. Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
    View in: PubMed
    Score: 0.021
  13. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
    View in: PubMed
    Score: 0.021
  14. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
    View in: PubMed
    Score: 0.021
  15. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.021
  16. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.020
  17. Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression? Am J Psychiatry. 2020 10 01; 177(10):891-894.
    View in: PubMed
    Score: 0.020
  18. Ketamine for depression clinical issues. Adv Pharmacol. 2020; 89:131-162.
    View in: PubMed
    Score: 0.019
  19. Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. Am J Psychiatry. 2020 02 01; 177(2):107-109.
    View in: PubMed
    Score: 0.019
  20. Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195.
    View in: PubMed
    Score: 0.019
  21. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012.
    View in: PubMed
    Score: 0.018
  22. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
    View in: PubMed
    Score: 0.017
  23. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.017
  24. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord. 2018 03 15; 229:1-13.
    View in: PubMed
    Score: 0.016
  25. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
    View in: PubMed
    Score: 0.016
  26. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
    View in: PubMed
    Score: 0.015
  27. Neurometabolic Abnormalities in Treatment-Resistant Depression. Am J Psychiatry. 2017 01 01; 174(1):3-5.
    View in: PubMed
    Score: 0.015
  28. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423.
    View in: PubMed
    Score: 0.014
  29. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81.
    View in: PubMed
    Score: 0.014
  30. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015 Mar; 29(3):181-8.
    View in: PubMed
    Score: 0.013
  31. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
    View in: PubMed
    Score: 0.013
  32. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. Neuroimage Clin. 2014; 4:326-35.
    View in: PubMed
    Score: 0.012
  33. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1.
    View in: PubMed
    Score: 0.012
  34. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.012
  35. The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther. 2013 Jun; 19(6):390-5.
    View in: PubMed
    Score: 0.012
  36. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012 Oct 01; 72(7):537-47.
    View in: PubMed
    Score: 0.011
  37. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204.
    View in: PubMed
    Score: 0.011
  38. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012 Sep; 25(9):1073-87.
    View in: PubMed
    Score: 0.011
  39. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9.
    View in: PubMed
    Score: 0.010
  40. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45.
    View in: PubMed
    Score: 0.009
  41. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6.
    View in: PubMed
    Score: 0.009
  42. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009 Apr; 22(3):251-8.
    View in: PubMed
    Score: 0.009
  43. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82.
    View in: PubMed
    Score: 0.009
  44. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 Feb; 166(2):140-5.
    View in: PubMed
    Score: 0.009
  45. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009 May 01; 65(9):792-800.
    View in: PubMed
    Score: 0.009
  46. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66.
    View in: PubMed
    Score: 0.009
  47. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 May 15; 148C(2):89-98.
    View in: PubMed
    Score: 0.008
  48. Anxiety and depression: leading edge of therapy. Mt Sinai J Med. 2008 May-Jun; 75(3):171-3.
    View in: PubMed
    Score: 0.008
  49. Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med. 2008 May-Jun; 75(3):263-75.
    View in: PubMed
    Score: 0.008
  50. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008 May-Jun; 75(3):248-62.
    View in: PubMed
    Score: 0.008
  51. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug; 33(9):2080-92.
    View in: PubMed
    Score: 0.008
  52. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92.
    View in: PubMed
    Score: 0.008
  53. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8.
    View in: PubMed
    Score: 0.008
  54. Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83.
    View in: PubMed
    Score: 0.008
  55. Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry. 2006; 67 Suppl 12:9-13.
    View in: PubMed
    Score: 0.007
  56. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81.
    View in: PubMed
    Score: 0.007
  57. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8.
    View in: PubMed
    Score: 0.007
  58. Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. J Clin Psychiatry. 2024 Nov 25; 85(4).
    View in: PubMed
    Score: 0.007
  59. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.007
  60. Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression. J Psychopathol Clin Sci. 2025 Apr; 134(3):228-238.
    View in: PubMed
    Score: 0.006
  61. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec; 9(12):1239-1248.
    View in: PubMed
    Score: 0.006
  62. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.006
  63. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024 Jun 07; 14(1):243.
    View in: PubMed
    Score: 0.006
  64. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 06 03; 7(6):e2417786.
    View in: PubMed
    Score: 0.006
  65. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004 Jun; 161(6):1119-21.
    View in: PubMed
    Score: 0.006
  66. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
    View in: PubMed
    Score: 0.006
  67. Stereo-Electroencephalography-Guided Network Neuromodulation for Psychiatric Disorders: The Neurophysiology Monitoring Unit. Oper Neurosurg (Hagerstown). 2024 Sep 01; 27(3):329-336.
    View in: PubMed
    Score: 0.006
  68. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
    View in: PubMed
    Score: 0.006
  69. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902.
    View in: PubMed
    Score: 0.006
  70. Stereo-EEG-guided network modulation for psychiatric disorders: Surgical considerations. Brain Stimul. 2023 Nov-Dec; 16(6):1792-1798.
    View in: PubMed
    Score: 0.006
  71. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475.
    View in: PubMed
    Score: 0.006
  72. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply. N Engl J Med. 2023 Sep 07; 389(10):961-962.
    View in: PubMed
    Score: 0.006
  73. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. J Affect Disord. 2023 10 15; 339:584-592.
    View in: PubMed
    Score: 0.006
  74. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325.
    View in: PubMed
    Score: 0.006
  75. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl Psychiatry. 2023 05 09; 13(1):159.
    View in: PubMed
    Score: 0.006
  76. One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 05 01; 6(5):e2312434.
    View in: PubMed
    Score: 0.006
  77. Differentiating depressed adolescent 24 h cortisol secretion in light of their adult clinical outcome. Neuropsychopharmacology. 2003 Jul; 28(7):1336-43.
    View in: PubMed
    Score: 0.006
  78. Decoding Depression Severity From Intracranial Neural Activity. Biol Psychiatry. 2023 09 15; 94(6):445-453.
    View in: PubMed
    Score: 0.006
  79. Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics. Adv Neurobiol. 2023; 30:287-297.
    View in: PubMed
    Score: 0.006
  80. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
    View in: PubMed
    Score: 0.006
  81. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
    View in: PubMed
    Score: 0.006
  82. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838.
    View in: PubMed
    Score: 0.006
  83. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
    View in: PubMed
    Score: 0.006
  84. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112.
    View in: PubMed
    Score: 0.006
  85. Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital. Behav Sleep Med. 2023 Mar-Apr; 21(2):129-141.
    View in: PubMed
    Score: 0.005
  86. Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251.
    View in: PubMed
    Score: 0.005
  87. A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. J Psychiatr Pract. 2021 11 05; 27(6):492-495.
    View in: PubMed
    Score: 0.005
  88. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4).
    View in: PubMed
    Score: 0.005
  89. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132.
    View in: PubMed
    Score: 0.005
  90. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
    View in: PubMed
    Score: 0.005
  91. Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. Transl Psychiatry. 2021 02 01; 11(1):88.
    View in: PubMed
    Score: 0.005
  92. Wearable technology: A promising opportunity to improve inpatient psychiatry safety and outcomes. J Psychiatr Res. 2021 03; 135:104-106.
    View in: PubMed
    Score: 0.005
  93. A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021 03; 46(4):820-827.
    View in: PubMed
    Score: 0.005
  94. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663.
    View in: PubMed
    Score: 0.005
  95. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
    View in: PubMed
    Score: 0.005
  96. Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review. J Affect Disord. 2020 08 01; 273:318-327.
    View in: PubMed
    Score: 0.005
  97. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.005
  98. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.005
  99. Psychotherapy for Mixed Depression and Mixed Mania. Psychiatr Clin North Am. 2020 03; 43(1):199-211.
    View in: PubMed
    Score: 0.005
  100. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.005
  101. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.005
  102. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 11 01; 176(11):923-930.
    View in: PubMed
    Score: 0.005
  103. Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Arch Clin Neuropsychol. 2019 Jun 01; 34(4):539-547.
    View in: PubMed
    Score: 0.004
  104. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255.
    View in: PubMed
    Score: 0.004
  105. Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. Psychophysiology. 2020 01; 57(1):e13356.
    View in: PubMed
    Score: 0.004
  106. Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philos Trans R Soc Lond B Biol Sci. 2019 02 18; 374(1766):20180132.
    View in: PubMed
    Score: 0.004
  107. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238.
    View in: PubMed
    Score: 0.004
  108. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.004
  109. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.004
  110. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 12 28; 18(1):82-84.
    View in: PubMed
    Score: 0.004
  111. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
    View in: PubMed
    Score: 0.004
  112. DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics. 2018 11 03; 10(1):136.
    View in: PubMed
    Score: 0.004
  113. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.004
  114. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019 04; 24(4):576-587.
    View in: PubMed
    Score: 0.004
  115. Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol. 2018 Jun; 38(3):200-206.
    View in: PubMed
    Score: 0.004
  116. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158.
    View in: PubMed
    Score: 0.004
  117. Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry. 2017 Dec 15; 82(12):866-874.
    View in: PubMed
    Score: 0.004
  118. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405.
    View in: PubMed
    Score: 0.004
  119. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746.
    View in: PubMed
    Score: 0.004
  120. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.004
  121. Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci. 2017 Oct; 267(7):697-707.
    View in: PubMed
    Score: 0.004
  122. Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. Bull Menninger Clin. 2016; 80(3):187-212.
    View in: PubMed
    Score: 0.004
  123. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
    View in: PubMed
    Score: 0.003
  124. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1082-90.
    View in: PubMed
    Score: 0.003
  125. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.003
  126. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.003
  127. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.003
  128. A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. J Neuropsychiatry Clin Neurosci. 2015; 27(2):93-103.
    View in: PubMed
    Score: 0.003
  129. Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci. 2015; 27(2):e170-1.
    View in: PubMed
    Score: 0.003
  130. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.003
  131. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014 Jun 21; 15:240.
    View in: PubMed
    Score: 0.003
  132. Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res. 2014 Oct; 57:51-7.
    View in: PubMed
    Score: 0.003
  133. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9.
    View in: PubMed
    Score: 0.003
  134. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7.
    View in: PubMed
    Score: 0.003
  135. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6.
    View in: PubMed
    Score: 0.003
  136. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013 Apr; 23(4):276-84.
    View in: PubMed
    Score: 0.003
  137. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70.
    View in: PubMed
    Score: 0.003
  138. Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry. 2011 Apr 15; 69(8):804-7.
    View in: PubMed
    Score: 0.003
  139. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5.
    View in: PubMed
    Score: 0.003
  140. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93.
    View in: PubMed
    Score: 0.002
  141. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 2010 Jul; 23(6):643-50.
    View in: PubMed
    Score: 0.002
  142. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009 Feb 03; 180(3):305-13.
    View in: PubMed
    Score: 0.002
  143. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9.
    View in: PubMed
    Score: 0.002
  144. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 Nov; 73(7):941-9.
    View in: PubMed
    Score: 0.002
  145. Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res. 2006 Jun 30; 147(1):27-39.
    View in: PubMed
    Score: 0.002
  146. Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. Biol Psychiatry. 2004 Aug 01; 56(3):198-204.
    View in: PubMed
    Score: 0.002
  147. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002 Nov 15; 52(10):1008-30.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.